Positive effect of alendronate on bone mineral density and markers of bone turnover in patients with rheumatoid arthritis on chronic treatment with low-dose prednisone: a randomized, double-blind, placebo-controlled trial

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Osteoporosis International

• Publication date

  2006-02-03

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s00198-005-0037-2PMID 16463007
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Use of Oral Corticosteroids and Risk of Fractures

  2005cited by this paper
• Activation of peroxisome proliferator-activated receptor γ inhibits IL-1β-induced mPGES-1 expression in human synovial fibroblasts by interfering with Egr-1

  2004cited by this paper
• Effects of rheumatoid arthritis on bone

  2003cited by this paper
• Glucocorticoids in the treatment of early and late RA

  2003cited by this paper
• Low-Dose Prednisone Therapy for Patients with Early Active Rheumatoid Arthritis: Clinical Efficacy, Disease-Modifying Properties, and Side Effects: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial

  2002cited by this paper
• The Comparative Efficacy of Drug Therapies Used for the Management of Corticosteroid‐Induced Osteoporosis: A Meta‐Regression

  2002cited by this paper
• Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women.

  2002cited by this paper
• Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs.

  2002cited by this paper
• Meta-Analyses of Therapies for Postmenopausal Osteoporosis

  2002cited by this paper
• Glucocorticoids in Rheumatoid Arthritis

  2002cited by this paper
• Use of Inhaled Corticosteroids and Risk of Fractures

  2001cited by this paper
• Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis.

  2001cited by this paper
• Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial.

  2001cited by this paper
• Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 Update: American College of Rheumatology Ad Hoc Committee on glucocorticoid-induced osteoporosis

  2001cited by this paper
• Effects of Risedronate Treatment on Bone Density and Vertebral Fracture in Patients on Corticosteroid Therapy

  2000cited by this paper
• Glucocorticoid-induced osteoporosis: pathogenesis and management

  2000cited by this paper
• Use of Oral Corticosteroids and Risk of Fractures

  2000cited by this paper
• Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.

  1999cited by this paper
• A metaanalysis on the use of bisphosphonates in corticosteroid induced osteoporosis.

  1999cited by this paper
• New Developments in the Pathogenesis and Treatment of Steroid‐Induced Osteoporosis

  1999cited by this paper
• Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group.

  1998cited by this paper
• Alendronate for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis

  1998influential reference
• Joint destruction after glucocorticoids are withdrawn in early rheumatoid arthritis. Arthritis and Rheumatism Council Low Dose Glucocorticoid Study Group.

  1998cited by this paper
• Serum immunoreactive-leptin concentrations in normal-weight and obese humans.

  1996cited by this paper
• American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid‐induced osteoporosis

  1996cited by this paper
• Comparison of semiquantitative visual and quantitative morphometric assessment of prevalent and incident vertebral fractures in osteoporosis

  1996cited by this paper
• Comparison of semiquantitative visual and quantitative morphometric assessment of prevalent and incident vertebral fractures in osteoporosis The Study of Osteoporotic Fractures Research Group.

  1996cited by this paper
• Calcium and Vitamin D3 Supplementation Prevents Bone Loss in the Spine Secondary to Low-Dose Corticosteroids in Patients with Rheumatoid Arthritis

  1996cited by this paper
• The effect of glucocorticoids on joint destruction in rheumatoid arthritis. The Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group.

  1995cited by this paper
• Pre-existing fractures and bone mass predict vertebral fracture incidence in women.

  1991cited by this paper
• Glucocorticoid-induced osteoporosis: pathogenesis and management.

  1990cited by this paper
• Revised criteria for the classification of rheumatoid arthritis.

  1990cited by this paper
• The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis.

  1988cited by this paper

• Mechanisms of osteoclast activation in inflammatory bone loss in rheumatoid arthritis

  2025cites this paper
• Clinical practice guideline for the prevention, diagnosis, and treatment of glucocorticoid-induced osteoporosis. Colombian Association of Rheumatology, 2023

  2024cites this paper
• Prevention and Treatment of Glucocorticoid-Induced Osteoporosis in adults: Recommendations From the European Calcified Tissue Society.

  2024cites this paper
• Guía de práctica clínica para la prevención, el diagnóstico y el tratamiento de la osteoporosis inducida por glucocorticoides. Asociación Colombiana de Reumatología, 2023

  2023cites this paper
• Argentine Guidelines for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis in Postmenopausal Women and Men Aged 50 Years and Older

  2023cites this paper
• Threshold based on bone mineral density for therapeutic decision-making in postmenopausal women and men over 50 years old under glucocorticoid therapy.

  2022cites this paper
• German Society of Rheumatology recommendations for management of glucocorticoid-induced osteoporosis

  2021cites this paper
• Rheumatoid Arthritis is a Risk Factor for Refracture in Patients with Fragility Fractures.

  2021cites this paper
• Challenges in the diagnosis and management of glucocorticoid‐induced osteoporosis in younger and older adults

  2021cites this paper
• Secondary Osteoporosis.

  2021cites this paper
• Empfehlungen der Deutschen Gesellschaft für Rheumatologie zum Management der Glukokortikoid-induzierten Osteoporose

  2021cites this paper
• Efficacy and safety of sodium RISedronate for glucocorticoid-induced OsTeoporosis with rheumaTOid arthritis (RISOTTO study): A multicentre, double-blind, randomized, placebo-controlled trial

  2020cites this paper
• Osteoporosis in Inflammatory Arthritides: New Perspective on Pathogenesis and Treatment

  2020cites this paper
• Osteoporosis in patients with rheumatoid arthritis: an update in epidemiology, pathogenesis, and fracture prevention

  2020cites this paper
• Meta-regression analysis of the efficacy of alendronate for prevention of glucocorticoid-induced fractures

  2020influential citation
• Efficacy and Safety of First- and Second-Line Drugs to Prevent Glucocorticoid-Induced Fractures: A Network Meta-Analysis.

  2019cites this paper
• Effect of TNF inhibitors on bone mineral density in rheumatoid arthritis patients receiving bisphosphonate: a retrospective cohort study

  2019cites this paper
• Current Treatments and New Developments in the Management of Glucocorticoid-induced Osteoporosis

  2019cites this paper
• Pharmacological Management of Osteoporosis in Rheumatoid Arthritis Patients: A Review of the Literature and Practical Guide

  2019cites this paper
• Korean Guideline for the Prevention and Treatment of Glucocorticoid-induced Osteoporosis

  2018influential citation
• Biometric, histomorphometric, and biochemical profile in atorvastatin calcium treatment of female rats with dexamethasone-induced osteoporosis

  2018cites this paper
• Perfil biométrico, histomorfométrico e bioquímico no tratamento com atorvastatina cálcica de ratas com osteoporose induzida com dexametasona

  2018cites this paper
• Osteoporosis in Rheumatologic Conditions and Inflammatory Disorders

  2017cites this paper
• Skeletal complications of rheumatoid arthritis

  2017cites this paper
• Bisphosphonates for steroid-induced osteoporosis.

  2016cites this paper
• Bone Turnover Markers and Glucocorticoid Treatments

  2016cites this paper
• Assessment of Distal Radius Bone Mineral Density in Osteoporosis Patients Receiving Denosumab, Including Those with Rheumatoid Arthritis and Those Receiving Oral Glucocorticoids

  2016cites this paper
• Alendronate prevents glucocorticoid-induced osteoporosis in patients with rheumatic diseases

  2016cites this paper
• Risk factors for established vertebral fractures in Japanese patients with rheumatoid arthritis: Results from a large prospective observational cohort study

  2015cites this paper
• Management of glucocorticoid-induced osteoporosis: clinical data in relation to disease demographics, bone mineral density and fracture risk

  2015cites this paper
• Current and future treatments of secondary osteoporosis.

  2014cites this paper
• Place des principaux marqueurs biologiques du remodelage osseux dans la polyarthrite rhumatoïde et la spondylarthite ankylosante : revue de la littérature☆

  2013cites this paper
• Best Practice & Research Clinical Endocrinology & Metabolism

  2013cites this paper
• Common bone turnover markers in rheumatoid arthritis and ankylosing spondylitis: a literature review.

  2013cites this paper
• Osteoporosis drug therapy strategies in the setting of disease-modifying agents for autoimmune disease

  2013cites this paper
• Bisphosphonates for the Prevention and Treatment of Osteoporosis in Patients with Rheumatic Diseases: A Systematic Review and Meta-Analysis

  2013cites this paper
• Periarticular and generalised bone loss in patients with early rheumatoid arthritis: influence of alendronate and intra-articular glucocorticoid treatment. Post hoc analyses from the CIMESTRA trial

  2013cites this paper
• [A comparison of the measurements with biochemical markers of bone turnover and bone mineral density in the assessment of the efficiency of osteoporosis treatment].

  2013cites this paper
• Biochemical Markers of Bone Turnover in Osteoporosis

  2013cites this paper
• Regulation of bone destruction in rheumatoid arthritis through RANKL-RANK pathways.

  2013cites this paper
• Once-monthly oral ibandronate provides significant improvement in bone mineral density in postmenopausal women treated with glucocorticoids for inflammatory rheumatic diseases: a 12-month, randomized, double-blind, placebo-controlled trial

  2012cites this paper
• Epidemiological aspects of rheumatoid arthritis patients affected by oral bisphosphonate-related osteonecrosis of the jaws

  2012cites this paper
• Are changes in bone mineral density different between groups of early rheumatoid arthritis patients treated according to a tight control strategy with or without prednisone if osteoporosis prophylaxis is applied?

  2012cites this paper
• Prevention of glucocorticoid-induced osteoporosis in immunobullous diseases with alendronate: a randomized, double-blind, placebo-controlled study.

  2012cites this paper
• Bisphosphonates: Focus on Inflammation and Bone Loss

  2012cites this paper
• Osteoclast activity and subtypes as a function of physiology and pathology--implications for future treatments of osteoporosis.

  2011cites this paper
• Selecting the optimal treatment for glucocorticoid-induced osteoporosis.

  2011cites this paper
• The role of interleukin-6 in rheumatoid arthritis-associated osteoporosis

  2010cites this paper
• Teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: an analysis by gender and menopausal status

  2009cites this paper
• Once-Weekly Oral Alendronate 70 mg in Patients with Glucocorticoid-Induced Bone Loss: A 12-Month Randomized, Placebo-Controlled Clinical Trial

  2009cites this paper
• Bone Loss : A 12-Month Randomized , Placebo-Controlled Clinical Trial Once-Weekly Oral Alendronate 70 mg in Patients with Glucocorticoid-Induced

  2009cites this paper
• Bisphosphonates in Patients with Glucocorticoids: Time for Implementation

  2009cites this paper
• Prevention of glucocorticoid-induced osteoporosis

  2009cites this paper
• Glucocorticoid-induced osteoporosis: treatment update and review

  2009cites this paper
• Effects of monthly intramuscular neridronate in rheumatic patients in chronic treatment with low-dose glucocorticoids.

  2009influential citation
• Op weg naar sterker bot

  2008cites this paper
• Rheumatoid Arthritis: A Female Challenge

  2008cites this paper
• Risedronate for prevention of bone mineral density loss in patients receiving high-dose glucocorticoids: a randomized double-blind placebo-controlled trial

  2008cites this paper
• Changes in hand and generalised bone mineral density in patients with recent-onset rheumatoid arthritis

  2008cites this paper
• Alendronate once weekly for the prevention and treatment of bone loss in Canadian adult cystic fibrosis patients (CFOS trial).

  2008cites this paper
• Effects of glucocorticoids on inflammation and arthritis

  2007cites this paper
• Bisphosphonates and glucocorticoids: effects on bone quality.

  2007cites this paper
• Cost-effectiveness analyses of anti-resorptive agents for management of glucocorticoid-induced osteoporosis and fractures: Empirical estimates from the 1996--2004 MEPS data and longitudinal projection from Markov modeling

  2007cites this paper
• Biochemical assessment of bone turnover and bone fragility in men

  2007cites this paper
• Prevention and treatment of glucocorticoid-induced osteoporosis

  2007cites this paper
• Does alendronate improve bone mineral density in patients with RA treated with glucocorticoids?

  2006cites this paper
• [Current osteoporosis treatment: reasons for adding vitamin D to alendronate].

  2006cites this paper
• American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid‐induced osteoporosis

  1996cites this paper